Razagilin (Azilekt) is an anti - Parkinsonian agent , a specific inhibitor of monoamine oxidase ( MAO type B). Refers to the second generation of drugs in this group. It is used in Parkinson’s disease and symptomatic parkinsonism . 14 times more selective for MAO-B than for MAO type A.
| Razagilin | |
|---|---|
| Rasagilinum | |
| Chemical compound | |
| Gross formula | C 12 H 13 N |
| CAS | |
| Pubchem | |
| Drugbank | |
| Classification | |
| Pharmacol. Group | Dopamine receptor agonist |
| ATH | |
| Dosage Forms | |
| 1 mg tablets | |
| Mode of administration | |
| orally | |
| Other names | |
| Azilekt | |
It is used mainly in the early forms of Parkinson's disease, in the presence of mild motor disorders. It is also possible its use in combination with other anti-parkinsonian drugs .